Rituximab may prevent long-term comorbidities in treatment of pemphigus

Rituximab is associated with higher protection against long-term cardiovascular and metabolic diseases, but similar in survival rate, compared with other adjuvant agents in the treatment of pemphigus, according to a study.
“Pemphigus is a potentially life-threatening autoimmune bullous disease that manifests with erosions and blisters in the skin and mucosal surfaces,” Khalaf Kridin, MD, PhD, of the Lübeck Institute of Experimental Dermatology at University of Lübeck in Germany, and colleagues wrote. “Despite the substantial drop in the 1-year mortality rates of

Rituximab is associated with higher protection against long-term cardiovascular and metabolic diseases, but similar in survival rate, compared with other adjuvant agents in the treatment of pemphigus, according to a study.
“Pemphigus is a potentially life-threatening autoimmune bullous disease that manifests with erosions and blisters in the skin and mucosal surfaces,” Khalaf Kridin, MD, PhD, of the Lübeck Institute of Experimental Dermatology at University of Lübeck in Germany, and colleagues wrote. “Despite the substantial drop in the 1-year mortality rates of